[Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
From 1977 to 1989, we measured serum beta-2-microglobulin (beta 2-MG) levels from 64 unselected and untreated patients, between 18 to 50-year-old, affected by Hodgkin's disease. Serum beta 2-MG level was measured by radioimmunoassay (Phadebas beta 2 microtest). Then, all patients received a chemotherapy such as MOPP or alternating MOPP/ABVD followed or not by radiotherapy. Elevated serum beta 2-MG level (> 2.4 mg/l) is associated with advanced stage disease (stage III-IV), presence of systemic symptoms and bulky tumor. Nevertheless, a multivariate analysis shows that the serum beta 2-MG level is the most significant prognostic indicator for disease free survival. The prognostic value of serum beta 2-MG is demonstrated for myeloma and non Hodgkin's lymphoma. A few authors have evaluated the prognostic impact of serum beta 2-MG in Hodgkin's disease. This study requires confirmation by multicentric and prospective trial.
Fleury
J
J
Centre Jean-Perrin, Clermont-Ferrand, France.
Tortochaux
J
J
Legros
M
M
Cure
H
H
Kwiatkowski
F
F
Ferrière
J P
JP
Travade
P
P
Dionet
C
C
Gaillard
G
G
Chassagne
J
J
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D001613:beta 2-Microglobulin / Q000032:analysis*
D014408:Biomarkers, Tumor; D001613:beta 2-Microglobulin
Valeur pronostique de la bêta-2-microglobuline dans la maladie de Hodgkin de l'adulte jeune.